Navigation Links
PRA International Adds Dr. Susan Stansfield as Executive Vice President
Date:9/5/2007

ng new business opportunities. Under Dr. Stansfield's management, the European operations achieved substantial increases in revenue, gross profit and operating margin.

Dr. Stansfield has also held senior management positions at Quintiles and Innovex, where she was responsible for business process improvement and managing full-service clinical research projects. Dr. Stansfield began her career in clinical research in various positions with the Wellcome Research Foundation, the Janssen Research Foundation, and Parke Davis.

Dr. Stansfield has a BSc in Physiology and Biochemistry from Nottingham University and a PhD in Neuropharmacology from Reading University.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements that are subject to risks and uncertainties relating to PRA International's future financial and business performance, as well as any other predictive statements that depend on future events or conditions, or that include words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "may," "will," "estimate" or similar expressions of futurity. You should not place undue reliance on any forward-looking statements, which represent the company's statements only as of the date of this news release and are not intended to give any assurance as to actual future events. Factors that might cause future events to differ include: operational and personnel challenges that could result from management changes; the ability to execute our strategy during management transitions; the ongoing need for early and late phase drug development services; project cancellations and timing issues; our ability to attract and retain qualified personnel; our ability to continue providing our services effectively, including the quality or accuracy of the data or reports provided and our ability to meet agreed-upon schedules; the ability and willingness of our clients to continue to spend on research a
'/>"/>

SOURCE PRA International
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. John Mendelsohn M.D, chosen for an International Award
11. Thailand To Procure Botulism Antitoxin Internationally
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Vitals.com 'Goes Red' for American Heart Month 2Health News:Vitals.com 'Goes Red' for American Heart Month 3Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 2Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 4
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Its Better to Give Than to Receive 55771 1Its Better to Give Than to Receive 55771 2Its Better to Give Than to Receive 55771 3Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 1Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 2Prostate Cancer Over Diagnosed 3A Study 55767 1Prostate Cancer Over Diagnosed 3A Study 55767 2Prostate Cancer Over Diagnosed 3A Study 55767 3